UNSPSC 51402601: Ipsapirone

This classification denotes a serotonin agonist and anxiolytic with the molecular formula C19H23N5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6J9B11MN0K, chemically known as 1,2-benzisothiazol-3(2h)-one, 2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-, 1,1-dioxide but generally known as ipsapirone, which bears US NIH Compound Identifier 56971. European Medicines Agency schedules Ipsapirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08290MIG.

UNSPSC 51402601 Ipsapirone is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and drug management systems procured to support public health initiatives, though the specific code designation does not align closely with the actual work being solicited. State and local governments using this code have solicited naloxone and drug deactivation systems for emergency response and harm reduction, generic multi-source pharmaceuticals and OTC products through cooperative purchasing vehicles, and direct-to-manufacturer prescription fulfillment capacity. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances administering on behalf of participating state and local government facilities across multiple jurisdictions.

Recent opportunities span Florida, Texas, and the Upper Midwest through a cooperative purchasing vehicle. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program that would bypass traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 with a March 26, 2026 response date to establish contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson), with awarded vendors effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness. All three solicitations require vendor compliance with federal and state pharmaceutical regulations, including cGMP certification, DSCSA compliance, and drug-free workplace requirements.